A candidate modified-live bovine coronavirus vaccine: safety and immunogenicity evaluation.
A modified-live vaccine against the respiratory form of bovine coronavirus (BCoV) infection was developed by progressive attenuation of a respiratory strain (438/06-TN). The vaccine was found to be safe as four colostrum-deprived newborn calves remained healthy after oronasal administration of ten doses of the vaccine. The immunogenicity of the vaccine was assessed by intramuscular injection of one vaccine dose to 30 BCoV-antibody negative 2-3-month-old calves. At 30 days post-vaccination, all vaccinated calves displayed high antibody titres against BCoV. Sequence analysis of the S gene of wild-type and cell-adapted 438/06-TN strain detected 10 nucleotide changes, 9 of which were non-synonymous.
Decaro
Nicola
N
Department of Public Health and Animal Sciences, Faculty of Veterinary Medicine of Bari, Strada per Casamassima km 3, 70010 Valenzano, Bari, Italy. n.decaro@veterinaria.uniba.it
Campolo
Marco
M
Mari
Viviana
V
Desario
Costantina
C
Colaianni
Maria Loredana
ML
Di Trani
Livia
L
Cordioli
Paolo
P
Buonavoglia
Canio
C
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control* / Q000821:virology; D002460:Cell Line; D018352:Coronavirus Infections / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D017938:Coronavirus, Bovine / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology; D008969:Molecular Sequence Data; D012141:Respiratory Tract Infections / Q000517:prevention & control / Q000662:veterinary / Q000821:virology; D017422:Sequence Analysis, DNA; D064370:Spike Glycoprotein, Coronavirus; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
D000914:Antibodies, Viral; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines